Analyst consensus rating
ArriVent BioPharma Analyst Rating: Strong Buy
AVBP is rated Strong Buy by 10 analysts with a $44.70 target. As of 2026-09-02.
Direct answer
ArriVent BioPharma's consensus rating is Strong Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $44.70.
Forecast evidence checked September 2, 2026.
Get free ArriVent BioPharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $30.34
- Average price target
- $44.70
- High price target
- $50.00
- Low price target
- $40.00
- Low target gap
- +31.8%
- Target upside
- +47.3%
- High target gap
- +64.8%
- Target range width
- 33%
- Consensus rating
- Strong Buy
- Analysts
- 10
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ArriVent BioPharma?
ArriVent BioPharma has a verified Strong Buy consensus. The same dataset has an average price target of $44.70.
How far are ArriVent BioPharma's low and high targets from the recorded price?
The low target implies +31.8%, while the high target implies +64.8%.
How many analysts are included in ArriVent BioPharma's consensus?
The verified consensus includes 10 analysts.
How is ArriVent BioPharma's target upside or downside calculated?
The average target of $44.70 is divided by the recorded price of $30.34, then one is subtracted to produce +47.3%. This does not guarantee a future return.
When was ArriVent BioPharma's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.